The study, published in Neurology and co-authored by Evergreen neurologist Lahar Mehta, MD, showed that disease-modifying treatments for MS only give patients one to two more months of good health over a 10-year period. Drugs for the treatments would have to be slashed by 67 percent to be cost-effective compared with prices in other industrialized nations, the release said.
U.S. patients also pay nearly three times more for one of the treatment drugs compared with patients in the United Kingdom.
Related Articles on Hospital Neurology:
Houston’s Texas Children’s Hospital Uses Lasers to Battle Epilepsy
Louisiana Hospitals Form Cardiology, Neurology Affiliation
5 Qualities Every Hospital Neurologist Should Have
